Radiology 2022 May 24:211836. Epub 2022 May 24.
From the Joint Department of Medical Imaging, University Health Network, Mount Sinai Hospital & Women's College Hospital, University of Toronto, 610 University Ave, Suite 3-920, Toronto, ON, Canada M5G 2M9 (A.B.D., P.V.H., C.O., U.M.); Division of Urology, Department of Surgery (A.F.), Department of Radiation Oncology (A.B.), and Department of Biostatistics (L.A.), Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada; and Department of Oncology, Western University, London, Canada (G.B.).
Background Data regarding 2-(3-{1-carboxy-5-[(6-[F]fluoro-pyridine 3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (F-DCFPyL) PET in primary staging of prostate cancer (PCa) are limited. Purpose To compare the performance of F-DCFPyL PET/CT or PET/MRI (PET) with bone scan and CT with or without multiparametric MRI (hereafter, referred to as conventional imaging) in the initial staging of men with unfavorable intermediate or high-risk PCa and to assess treatment change after PET. Materials and Methods This prospective study evaluated men with biopsy-proven, untreated, unfavorable intermediate or high-risk PCa with 0 to four metastases or equivocal for extensive metastases (more than four) who underwent PET between May 2018 and December 2020. Read More